Company intelligence / Profile preview

Deep Breathe

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Deep Breathe has developed a suite of AI-powered tools that automate the interpretation of portable lung ultrasound images, demonstrating high sensitivity in detecting conditions like pneumothorax. Their technology was rapidly adapted during the COVID pandemic to distinguish between COVID and other pulmonary diseases with accuracy surpassing physician performance at the time. The company recently won first place at the US Army’s xTechInternational competition for its innovation in point-of-care diagnostics[6][7]. Peer-reviewed studies support their approach, but products are pending FDA and Health Canada approval[1][2][7].

Therapeutic areas: Pulmonology
Modalities: DeviceNon-pharmacological therapy (AI-powered diagnostic tool)
Industry: Digital Health Medical Devices

Partnerships

Leading ultrasound manufacturers

Beyond the preview

Go deeper on Deep Breathe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deep Breathe.

Explore the full profile